Tumor microenvironment complexity: emerging roles in cancer therapy.
暂无分享,去创建一个
Melissa H Wong | Melody A Swartz | L. Coussens | M. Swartz | M. Wong | Y. DeClerck | F. Yull | Noriho Iida | S. Sangaletti | Edward W. Roberts | Lisa M Coussens | Noriho Iida | Edward W Roberts | Sabina Sangaletti | Fiona E Yull | Yves A DeClerck
[1] Mark T. W. Ebbert,et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.
[2] M. Bertagnolli,et al. Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. , 2012, Cancer research.
[3] W. Dougall. Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis , 2011, Clinical Cancer Research.
[4] Naveena Singh,et al. Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.
[5] Michael C. Ostrowski,et al. NF-kappaB activation within macrophages leads to an anti-tumor phenotype in a mammary tumor lung metastasis model , 2011, Breast Cancer Research.
[6] Karin Jirström,et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.
[7] Melody A. Swartz,et al. Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21 , 2010, Science.
[8] B. Fingleton,et al. Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.
[9] D. Steinhilber,et al. Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. , 2011, The Journal of clinical investigation.
[10] Michael Karin,et al. Inflammation meets cancer, with NF-κB as the matchmaker , 2011, Nature Immunology.
[11] T. Sacktor. How does PKMζ maintain long-term memory? , 2011, Nature Reviews Neuroscience.
[12] G. Rabinovich,et al. Neuroblastoma triggers an immunoevasive program involving galectin‐1‐dependent modulation of T cell and dendritic cell compartments , 2012, International journal of cancer.
[13] Robert A. Gatenby,et al. Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.
[14] S. Hewitt,et al. Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. , 2010, Archives of pathology & laboratory medicine.
[15] M. Swartz,et al. Role of Lymphatic Vessels in Tumor Immunity: Passive Conduits or Active Participants? , 2010, Journal of Mammary Gland Biology and Neoplasia.
[16] D. Ribatti. From the discovery of Vascular Endothelial Growth Factor to the introduction of Avastin in clinical trials - an interview with Napoleone Ferrara , 2011 .
[17] M. Detmar,et al. Interaction of tumor cells and lymphatic vessels in cancer progression , 2012, Oncogene.
[18] Erik Sahai,et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. , 2011, Cancer cell.
[19] George Coukos,et al. Cancer immunotherapy comes of age , 2011, Nature.
[20] Matthew J. Paszek,et al. Balancing forces: architectural control of mechanotransduction , 2011, Nature Reviews Molecular Cell Biology.
[21] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[22] M. Colombo,et al. SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. , 2011, The American journal of pathology.
[23] R. DuBois,et al. COX-2 inhibition and colorectal cancer. , 2004, Seminars in oncology.
[24] H. Dvorak,et al. Tumor microenvironment and progression , 2011, Journal of surgical oncology.
[25] A. Witteveen,et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test , 2006, BMC Genomics.
[26] L. Coussens,et al. B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis , 2011, Proceedings of the National Academy of Sciences.
[27] N. Bertos,et al. Breast cancer - one term, many entities? , 2011, The Journal of clinical investigation.
[28] M. Detmar,et al. Watching lymphatic vessels grow by making them glow , 2011, Cell Research.
[29] G. Friedman,et al. Helicobacter pylori infection and the risk of gastric carcinoma. , 1991, The New England journal of medicine.
[30] Brian Keith,et al. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression , 2011, Nature Reviews Cancer.
[31] W. Dougall. Osteoclast-dependent and-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis , 2011 .
[32] N. Ferrara. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti. , 2011, The International journal of developmental biology.
[33] M. Wong,et al. Fusion between Intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. , 2011, Cancer research.
[34] E. Sahai,et al. Cell communication networks in cancer invasion. , 2011, Current opinion in cell biology.
[35] D. Lyden,et al. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. , 2011, Seminars in cancer biology.
[36] G. Shurin,et al. Regulatory dendritic cells in the tumor immunoenvironment , 2012, Cancer Immunology, Immunotherapy.
[37] A. Ruddell,et al. B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma. , 2011, Neoplasia.
[38] J. Fox,et al. Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer , 2010, Mucosal Immunology.
[39] Laurence Zitvogel,et al. Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.
[40] Kenneth J Pienta,et al. Mechanisms of cancer cell metastasis to the bone: a multistep process. , 2011, Future oncology.